Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities

被引：35

作者：

Roberts, Kate ^{[1
]}

Culleton, Vanessa ^{[1
]}

Lwin, Zarnie ^{[1
,2
,3
]}

O'Byrne, Kenneth ^{[4
,5
]}

Hughes, Brett G. M. ^{[1
,2
,3
]}

机构：

[1] Prince Charles Hosp, Canc Care Serv, Brisbane, Qld 4032, Australia

[2] Royal Brisbane & Womens Hosp, Herston, Qld, Australia

[3] Univ Queensland, Sch Med, Brisbane, Qld, Australia

[4] Princess Alexandra Hosp, Brisbane, Qld, Australia

[5] Queensland Univ Technol, Brisbane, Qld, Australia

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 13卷 / 04期

关键词：

autoimmune; CTLA4; immunotherapy; PD1; PDL1; CELL LUNG-CANCER; ADVANCED MELANOMA; METASTATIC MELANOMA; ADVERSE EVENTS; UNTREATED MELANOMA; PHASE-3; TRIAL; HEPATITIS-C; OPEN-LABEL; IPILIMUMAB; NIVOLUMAB;

D O I：

10.1111/ajco.12698

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint inhibitors have recently emerged as an exciting new treatment paradigm across a broad spectrum of malignancies. This new class of agents also challenges oncologists with a unique set of immune-based toxicities. Early recognition and precise management of these toxicities can result in better outcomes, with minimization of toxicity and harm to the patient. This article provides a comprehensive review of immune-based toxicities caused by immune checkpoint inhibitors, including recommendations for their investigation and guidelines for specific management.

引用

页码：277 / 288

页数：12

共 65 条

[1] Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis [J].

Abdel-Rahman, Omar ;

Fouad, Mona .

THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2016, 10 (03) :183-193

[2] Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis [J].

Abdel-Rahman, Omar ;

ElHalawani, Hesham ;

Fouad, Mona .

FUTURE ONCOLOGY, 2015, 11 (17) :2471-2484

[3] Pancreatitis Secondary to Anti-Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT [J].

Alabed, Yazan Z. ;

Aghayev, Ayaz ;

Sakellis, Christopher ;

Van den Abbeele, Annick D. .

CLINICAL NUCLEAR MEDICINE, 2015, 40 (11) :e528-e529

[4]

[Anonymous], COMM TERM CRIT ADV E

[5] Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor [J].

Belum, V. R. ;

Benhuri, B. ;

Postow, M. A. ;

Hellmann, M. D. ;

Lesokhin, A. M. ;

Segal, N. H. ;

Motzer, R. J. ;

Wu, S. ;

Busam, K. J. ;

Wolchok, J. D. ;

Lacouture, M. E. .

EUROPEAN JOURNAL OF CANCER, 2016, 60 :12-25

[6]

Berman David, 2010, Cancer Immun, V10, P11

[7]

BMS, 2011, IP US FULL PRESCR IN

[8]

BMS, 2014, NIV US FULL PRESCR I

[9] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[10]

Bot Ilja, 2013, Pract Neurol, V13, P278, DOI 10.1136/practneurol-2012-000447

← 1 2 3 4 5 6 7 →